A human arsenal is loaded with several valuable elements, but if we take a second to really assess the picture, we’ll see how none of them hold as much value as our ability to grow on a consistent basis. You see, when an individual grows under every possible situation, they eventually become eligible for some significant milestones along the way. This dynamic is also pretty evident in whatever we have achieved so far, with one notable piece of testimony coming from a concept called technology. In fact, technology’s testimony stands a cut above the rest, and it does so for reasons that go well beyond just its ingenious skill-set. To contextualize the statement, we must also look at how the creation used those skills to impact an entire spectrum, including the highly-critical area of healthcare. Technology’s foray into healthcare, interestingly enough, came at a time when the sector was really struggling to hold up against an outright obsolete structure. By instilling new and smarter ideas, however, the creation was successful in shaking up that reality. This pattern has only grown stronger over time, and one recent FDA approval does a lot to further the stated trend.
iRhythm Technologies, a leading digital healthcare solutions company focused on the advancement of cardiac care, has officially announced that it has received the FDA 510(k) clearance for the ZEUS (Zio ECG Utilization Software) System of its Zio watch. The Zio watch, which was by the way created on the back of a close collaboration with Alphabet precision health company, Verily, is a sensor-based wearable for noninvasive, clinical grade, long-term continuous monitoring for atrial fibrillation (AFib). It uses a dedicated AI-based algorithm to fulfill various advance healthcare objectives like addressing clinician workflows, care pathways, and the overall patient experience. Mind you, the function of Zio watch isn’t just limited to detecting AFib, but it also characterizes the amount of AFib over time, therefore offering a much more extensive lowdown on an individual’s health. Once the stated evaluations are completed, the technology prepares a preliminary report that is then sent to the patient’s clinicians for a timely diagnosis.
“We are incredibly excited about this important milestone as we make progress in bringing a new monitoring platform to patients who can benefit from it. There is a clear need in the market today for a clinical grade, long-term and noninvasive monitoring solution,” said Quentin Blackford, CEO and President of iRhythm. “iRhythm is focused on redefining the standard of care with earlier insight to predict and prevent disease, and the Zio Watch with ZEUS System provides clinicians a platform that has the potential to meaningfully improve patients’ lives.”
Slated to have a limited launch in 2023, the Zio watch will be equipped to work alongside Zio monitors, as well as the wider Zio service.
